Exopharm Share Price and Company Fundamentals

0.015 (3.297%)
52 week
0.285 - 1.0

Last traded: Today at 5:48 AM

Exopharm Limited, a clinical-stage company, develops transformative medicines based upon extracellular vesicles (EVs) in Australia. The company's technology includes extracellular vesicle positioning system that allows specific molecules to be attached to the surface of exosomes to guide them to target tissues or cell types; leveraging oligonucleotide packing for amplified dosing, which enables specific RNA molecules to be preferentially loaded into exosomes as a therapeutic cargo; ligand-based exosome affinity purification that isolates and purifies exosomes from biofluids like blood and cell culture media. Its engineered EVs products comprise Fortrexo CoV for the treatment of SARS-CoV-2 infection; Cognevo for the treatment of neuro degeneration; and PlexoDox for the treatment of cancer. Exopharm Limited has a research collaboration with Showa Denko Materials Co., Ltd. The company was incorporated in 2013 and is based in Melbourne, Australia.

Key Metrics

PE ratio


PB ratio


Dividend yield



Market cap


Enterprise value


Company profile

Primary activitiesBiopharmaceutical research with a primary focus on developing and commercialising exosomes as therapeutic agents.
Industry / SectorBiotechnology / Healthcare
Full time employees41
Mailing address31 Queen Street Level 17 Melbourne VIC 3000 Australia
Phone / Fax61 3 9111 0026 /


Exopharm does not pay dividends.

Company Executives

As of Sep 2021, following are the company executives and directors listed on Exopharm.

NameTitleAgeTotal Pay
Dr. Ian E. Dixon M.A.I.C.D., M.B.A., MBA, Ph.D.Founder, Technology Co-Founder, CEO MD & Director430.38k
Dr. Gregor Lichtfuss M.Sc.Co-Founder & Bus. Services Mang.228.54k
Dr. Christopher Baldwin Ph.D.Deputy CEO & Chief Commercial Officer377.56k
Ms. Elizabeth McGregor B.A., M.B.A.Company Sec. & Non-Exec. Director36.81k
Mr. David OxleyPres of International

Profitability and management effectiveness

Profit margin


Operating margin


Return on assets


Return on equity


Profitability ratios are a class of financial metrics that are used to assess a business's ability to generate earnings relative to its revenue, operating costs, balance sheet assets, and shareholders' equity over time, using data from a specific point in time.

The return on equity signifies how well the management is running the company in terms of capital management. The ideal return on equity is greater than 10%. The return on equity is calculated as net income divided by total share holders equity.

Valuation and Trading Info

The market capitalization of Exopharm is 73.89M and its enterprise value is 60.11M. The enterprise value to revenue ratio of EX1 is 14.34.

The EX1's stocks Beta value is 0.96 making it 4% less volatile compared to ASX market index. Technology stocks and small caps tend to have higher betas than the market benchmark. This indicates that adding the stock to a portfolio will increase the portfolio’s risk, but also increase its expected return. On the other hand utility stocks often have low betas because they tend to move more slowly than market averages.

Companies similar to Exopharm (EX1)

Exopharm (ASX:EX1) Frequently Asked Questions

1. What is Exopharm's Stock Symbol?

Exopharm trades on ASX under the ticker symbol "EX1".

2. What is Exopharm's stock price today?

One share of EX1 stock can currently be purchased for approximately $0.47.

3. How can I contact Exopharm?

Exopharm's mailing address is 31 Queen Street Level 17 Melbourne VIC 3000 Australia. The company can be reached via phone at 61 3 9111 0026.

4. What is Exopharm's official website?

The official website of Exopharm is http://www.exopharm.com.

5. Which share registry manages Exopharm's stock?

Exopharm's stock is managed by AUTOMIC REGISTRY SERVICES.